![]() | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Dopamine receptor agonist |
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. [1] [2] It was originated by Pfizer and is under development by Cerevel Therapeutics. [1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors. [1] [2] [3] It is taken via oral administration. [1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy. [1]
![]() | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Dopamine receptor agonist |
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. [1] [2] It was originated by Pfizer and is under development by Cerevel Therapeutics. [1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors. [1] [2] [3] It is taken via oral administration. [1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy. [1]